RecruitingPhase 2NCT07509086
IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia
Studying Plasma cell leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- The First Hospital of Jilin University
- Intervention
- IL-15-armored CAR-T cells(biological)
- Enrollment
- 25 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2025 – 2029
Study locations (1)
- The First Hospital of Jilin University, Changchun, Jilin, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07509086 on ClinicalTrials.govOther trials for Plasma cell leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06517017Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple MyelomaUniversity of Utah
- RECRUITINGPHASE2NCT07106684ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell LeukemiaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGEARLY PHASE1NCT06730256A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell LeukemiaThe First Affiliated Hospital of Soochow University
- RECRUITINGNANCT07052916A Music Therapy Study for Blood Cancer Survivors With Cognitive DifficultiesMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE2, PHASE3NCT07202091Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)Monash University
- RECRUITINGEARLY PHASE1NCT06718270a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell LeukemiaShanghai Changzheng Hospital
- RECRUITINGPHASE2NCT06140966Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple MyelomaUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPHASE2NCT05979363A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell LeukemiaInstitute of Hematology & Blood Diseases Hospital, China